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Biopharmaceuticals innovation molecules have changed the course of a large number of 
chronic diseases. Many of these molecules became Gold Standards in oncology, 
rheumatology and other illness. However, their cost makes these drugs unattainable for 
most patients, and often put the health systems' budgets at risk. This study takes the 
anaemia due to Chronic Renal Failure disease (CRFD) as an example to a rational selection 
of treatment with erythropoietin (EPO) and compares the trade brand mark of this drug 
with biosimilars option.  
Prescriptions of EPO in 394 patients with CRFD were submitted to a protocol of rational 
selection based in efficacy/risk ratio demonstration. This protocol was able to reduce that 
initial number to 91 cases that could really benefited with EPO treatment. These patients 
were included in a cohort study that compared EPO trade mark with biosimilars option. 
The experience demonstrated equal clinical outcomes in both groups but a reduction to 
half the original cost when biosimilars were dispensed. Biosimilars demonstrated to be a 
cheap and safe option to increase medicine access for anaemia associated to CRFD. 









Biopharmaceuticals products are drugs containing substances derived from biotechnology 
as active ingredients1. These molecules were developed back in the early 1980s and 
certainly changed the course of a large number of chronic diseases and have inadvertently 
been introduced into the daily lives of patients suffering from hepatitis, rheumatoid 
arthritis, chronic kidney failure, diabetes, multiple sclerosis, cancer and other pathologies 
that were previously untreated. 
Traditional medicines are made by chemical synthesis processes and have simple chemical 
structures. In contrast, biotechnology drugs are manufactured using microorganisms such 
as bacteria or mammalian cells. The success of this technology was such that in the last 
decade have introduced to the market more than 200 therapeutic molecules existing on a 
global scale. 
Many of these molecules became Gold Standards in oncology, rheumatology and other 
high-impact diseases, however, their cost are up to 200,000 USD per year (almost 100 
times cost of a traditional drug)2. This high cost is usually due to the complexity of its 
structure, as well as the manufacturing, the control and the research processes3.  Those 
Pharmaceutical companies that develop a new products claim by itself the patent of the 
discovery4,5, and anyone that wants to produce these molecules, has to pay a high fee. 
Hence, this situation avoids market competition and sustain over time soaring prices that 
health systems may not assimilate in the future. For this reason, the access to these 
medicines will not be guarantee for everyone. Governments must arbitrate the measures 
to provide suitable coverage to the population with these needs. One of the best 
strategies to do so is the adoption of a policy on the rational use of medicines. This means 
select medicines with proven efficacy and with the best benefit/risk/cost ratio. Once the 
medicine is selected, other strategies are related to the choice of the medicine provided 
by the market. Due to the fact that some patents of the original biological molecules have 
recently expired, or are due to expire, it exists opportunities for small or local 
pharmaceutical companies to develop and produce either generic or biosimilars drugs. 
Biosimilars differ from conventional generic drugs in various aspects, such as the size of 
the active substance, its complexity, the nature of the manufacturing process and the fact 
that they are not identical to the original products6. Biosimilars might be then 
pharmaceutical alternatives of "innovative" products at a lower cost7-10.  In order to 
demonstrate so, we performed a strategy o RUM followed by a cohort study in which 
biosimilars were compared with original molecules in terms of clinical outcomes and cost 




Type of study 
The proposal of the study was framed in stages: the first one based in a rational selection 
of medicines strategy in order to validate the Erythropoietin (EPO) indication to treat the 
anaemia associate to Chronic Renal Failure disease (CRFD) in patients under 
haemodialysis.  The second stage was the development of a cohort study in which patients 
were divided in two groups based on the type Erythropoietin (EPO) used to treat the 
disease either original trade mark or biosimilars molecule. Clinical outcome and cost of 
treatment were the main variables included in the analysis.   
Population 
Social security beneficiaries of Buenos Aires State coverage, affected by anaemia 
associated with chronic renal failure in haemodialysis in whom EPO was indicated were 
included in the study. 
Inclusion and Exclusion Criteria of patients to the study 
For the present study, authors adopted the recommendations of clinical practice of the 
Latin American Society of Nephrology and Hypertension (SLANH) for the treatment of 
anaemia in patients with chronic kidney disease8. 
Period of study  
01/01/2015 to 31/12/2016 
Cost evaluation 
The cost of the medicines was considered as defined daily dose (DDD) for patient treated. 
The baseline costs were extrapolated to a national coverage in order to determinate the 
global cost for Argentina.  To compare the cost of each type of EPO ampoules, it was 




The number of patients with CRFD in haemodialysis living in Buenos Aires State during the period 
of study was 10882 patients (4640 females / 6242 males). 1451 of those patients had social 
security coverage. Prescription of EPO was performed in 394 of those patients. However, after 
submitting the prescriptions to a RUM analysis the amount that really needed EPO were 91 
patients. Patients excluded had either iron or folic acid deficiency or lack the strict criteria of use 
of EPO. From the 91 patients, only 60 of them had access to the EPO treatment and were 
included in the present study (35 men and 25 women). Their average age was 57 +/- 14 
years old. Two groups were considered according to the type of EPO dispensed (either 
original molecule or biosimilars-figure 1). Basal blood test was performed in all cases 
(table 1).   
 





Table 1. Baseline data  
Group according to 










Trade mark 30 9.3 ± 0.9 28 ± 4 598 ± 303 88,4± 1 37 ± 13 159 ± 22 
Biosimilars 30 9.1 ± 1.1 27 ± 1 584 ± 202 90,5± 7 36 ± 19 156 ± 46 
Statistical difference NS NS NS NS NS NS 
EPO: Erithropoietin; Hb: Hemoglobin; Ht: Hematocrit;  TSAT: Transferrin;  TIBC: total iron transport capacity 
 
Clinical Impact 
(in terms of Hb recovery) 
Cost Analysis Group A  (Trade Mark molecule)                
Group B  (Biosimilars drugs) 
Ferritin values observed ranged from 173 to 987 ng/ml, transferrin saturation (TSAT) 
oscillated between 19 and 78%. Serum iron also showed marked oscillations (76,8-182 
%). Although serum iron profile disparity was observed in both groups, these results were 
similar in both groups and not find significant differences were detected (table 1).  
  
The defined daily dose for Erythropoietin was 1000 Units (or its equipotent dose for 
biosimilars molecules), assuring a weekly dose of 6000 UI to complete the period of 
treatment established before the new blood control test. 
 
After 4 weeks of treatment, five patients were excluded from protocol (2 from trade Mark 
drug and 3 from biosimilars). The cause of these exclusions was protocol violation in all 
cases (patients did not respect the weekly dose established in the protocol).  
Results of blood test after a month of EPO treatment is shown in table 2.  It is also shown 
in that table, the improvement of performance status referred by the patients in relation 
to basal survey.  
     
Table 2. Treatment Clinical and Laboratory Outcome  
Group 
according to 
type of EPO 
n Hb Ht Ferritin Serum 
Iron 




























NS NS NS NS NS NS 0.04 
    EPO: Erythropoietin; Hb: Hemoglobin; Ht: Hematocrit;  TSAT: Transferrin saturation;  TIBC: total   iron binding 
capacity test. PS: Performance Status 
 
In relation to the cost of EPO, the first surprising observation is that for the presentation 
of ampoules of 2000 U, there is a difference of 340% between the costs of the original 
biological molecule, but the most remarkable tip was that even between biosimilars, the 
cost of more expensive option doubles the cheaper one. (21.77 USD vs 9.6 USD per 
ampoule of 2000 U) (table3).  
 
                                    Table 3 Cost analysis of EPO molecules 
 
Type of EPO Price USD 
Original Brand 22.28 
Biosimilar 1 12.26 
Biosimilar 2 21.77 
Biosimilar 3 9.6 
Presentation dose were syringe of 2000 UI for all cases 




Biosimilars pricing worldwide has commonly seen cost reductions up to 30% less than 
the reference products11-12, however our shows that there are still opportunities for 
biosimilars to provide even more significant discounts in certain countries. 
Most of the available literature on biosimilars has focused on the critical analysis of 
their specific market authorization procedure. Only few papers are addressed to 
demonstrate biosimilars competition and its subsequent impact on price erosion11-13. 
Companies that produce brand-name drugs are gradually abandoning their strategy of 
competing with their biosimilars counterparts for a policy aimed at improving their 
formulations, expression systems and the delivery methods20.  For example, Amgen's 
first-generation epoetin alfa which has multiple weekly doses are changing its strategy 
towards the development of new products (second-generation epoetin alfa) that provides 
an only weekly injection. This fact opens an scenario that opens new opportunities to 
incorporate classical biosimilars products in emerging markets at a lower price to treat 
well known disease like anaemia in chronic renal failure disease (CRFD) in which outcome 
benefits was already demonstrated. 
CRFD is a global public health problem. The most serious manifestation of renal 
disease is chronic renal failure that requires dialysis14,15.  At the global level, the 
prevalence of Chronic Kidney Disease (CKD) in the elderly of 20 years is 17%. The CRFD 
usually coexists with anaemia that needs high cost medicines like Erythropoietin (EPO) to 
be treated.  
In our work is shown that the rational selection of patients that should receive EPO is 
the most cost/effectiveness decision to be made. In fact, after the selection process from 
the 394 prescriptions done, only in 91 patients the EPO was kept. That means that 76.9% 
of the prescriptions were inconsistent with the indication criteria.  
On the other hand, once the validation of the treatment is demonstrated, the procedure 
of RUM continues with the selection of the type of EPO it should be used according to 
cost/effectiveness analysis.  Here is where biosimilars have their place.   
The present study shows that when biosimilars were used instead of brand market 
molecules, it could be obtained the same clinical outcomes and also save money of health 
service budgets in concept of treatment. In economical terms, it could be said that using 
the selection procedure, there is a net saving per year of 844.800 USD only in this drug 




This study reflects that rational use of medicine procedure may help to select the best 
treatment for anaemia in CRFD. The RUM procedure performed in this study included the 
use of a biosimilars selection, which was able to reduce the treatment cost by half of the 
original price. Policies that promote biosimilars use and production in developing 
countries like Argentina might be reflected in saving public budget of the health system, 
which can be a way of include more population into the health care coverage, increasing 
their access to health services. 
 
Policy makers have then a challenge for in the coming years that will be to set effective 
measures leading to improved biosimilar uptake. Expectations on future savings for 
emerging markets la Argentina related to forthcoming biosimilars are a key driver for 
interest and concern from national authorities on biosimilar current market penetration, 





1. Bingham A.; Ekins S. Competitive collaboration in the pharmaceutical and biotechnology 
industry. Drug Discov Today. 2009; 14, 23/24: 1079-1081.   
2. Goldstein DA, Stemmer SM, Gordon N. The cost and value of cancer drugs – are new 
innovations outpacing our ability to pay? Israel Journal of Health Policy Research. 2016; 
5:40.  
3. Marin, GH  and  Polach MA. High-cost drugs: analysis and proposals for Mercosur 
countries. Rev Panam Salud Publica . 2011; 30, 2: 167-176. 
4. Correa C. Intellectually Property Rights, the WTO and Developing Countries. The TRIPs 
Agreement and Policy Options, Zed Books Ltd, London. 2000.  
5. Correa C. “Implications of bilateral free trade agreements on access to medicines” en 
Bulletin of World Health Organization, vol.84 N.5, Ginebra.2006.  
6. 2. Rovira J, Espín J, García L, Olry de Labry A. The Impact of Biosimilars’ Entry in the EU 
Market. Granada: Andalusian School of Public Health; 2011.  
7. Lavarello, P. (2014), “Convergencia de paradigmas biotecnológicos y estrategias de los 
grupos líderes mundiales”, Problemas del desarrollo, 45 (177), 9-35. 
8. Pisano, G. P. Science business: The promise, the reality, and the future of biotech. Harvard 
Business Press. 2006. 
9. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health 
problem: approaches and initiatives — a position statement from Kidney Disease 
Improving Global Outcomes. Kidney Int 2007; 72:247-59. 
10. 3. Borget I, Grivel T. Biosimilaires et facteurs medico-economiques. Bull. Cancer. 
2010;97(5):589–595. 
11. 18. Farfan-Portet M-I, Gerkens S, Lepage-Nefkens I, Vinck I, Hulstaert F. Are biosimilars the 
next tool to guarantee cost-containment for pharmaceutical expenditures? The European 
Journal of Health Economics. 2014;15(3):223-228.    
12. 17. IMS Institute for Healthcare Informatics. Declining medicine use and costs: for better 
or worse? A review of the use of medicines in the United States in 2012. May 2013.  
13. Aapro M, Cornes P, Sun D, Abraham IT. Comparative cost efficiency across the European 
G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage 
chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol. 2012 May; 
4(3):95-105  
14. Yu  B. Greater Potential Cost Savings With Biosimilar Use. Am J Manag Care. 
2016;22(5):378 
15. Carlini R, Obrador G, Campistris N et al.The First Report of The Latin American Society of 
Nephrology and Hypertension (SLANH) Anemia Committee in Chronic Hemodialysis 
Patients. Nefrologia (English Version) 2014; 34:96-104. 
16. Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag Care. 2015; 
(16 Suppl):s331-40. 
17.  Lovenworth SJ. The new biosimilar era: the basics, the landscape, and the future. 
Bloomberg Law. 2012. http://about.bloomberglaw.com/practitioner-contributions/the-
new-biosimilar-era-the-basics-the-landscape-and-the-future/ Accessed December 14th, 
2017. 
